There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Plus Therapeutics (PSTV – Research Report), Beyond Air (XAIR – Research Report) and Ovid Therapeutics (OVID – Research Report) with bullish sentiments.
Plus Therapeutics (PSTV)
In a report released today, Justin Walsh from JonesTrading maintained a Buy rating on Plus Therapeutics, with a price target of $32.00. The company’s shares closed last Friday at $1.52, close to its 52-week low of $0.97.
According to TipRanks.com, Walsh is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Plus Therapeutics with a $14.67 average price target, an 884.6% upside from current levels. In a report issued on November 1, H.C. Wainwright also maintained a Buy rating on the stock with a $8.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Beyond Air (XAIR)
In a report released today, Marie Thibault from BTIG reiterated a Buy rating on Beyond Air, with a price target of $13.00. The company’s shares closed last Friday at $2.40, close to its 52-week low of $2.06.
According to TipRanks.com, Thibault has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Beyond Air with a $12.33 average price target.
Ovid Therapeutics (OVID)
JonesTrading analyst Sean Kim PhD maintained a Buy rating on Ovid Therapeutics today and set a price target of $6.00. The company’s shares closed last Friday at $3.63.
According to TipRanks.com, PhD is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ovid Therapeutics with a $7.00 average price target, which is a 95.0% upside from current levels. In a report issued on October 19, Ladenburg Thalmann & Co. also reiterated a Buy rating on the stock with a $7.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PSTV:
- Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to Rhenium (186Re) Obisbemeda for the Treatment of Breast Cancer with Leptomeningeal Metastases
- Biotech Alert: Searches spiking for these stocks today
- Plus Therapeutics announces share repurchase program up to $500K
- Plus Therapeutics Announces Share Repurchase Program
- Plus Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
